Trials / Completed
CompletedNCT02452684
Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients (Study LUN01S)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,876 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and efficacy of administration of eszopiclone for 4 weeks in insomnia patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eszopiclone | The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-11-11
- Completion
- 2015-12-22
- First posted
- 2015-05-25
- Last updated
- 2018-09-07
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02452684. Inclusion in this directory is not an endorsement.